Analytical cohort study on splenomegaly and cytopenias in myeloproliferative disorders

TL;DR

This study explores how an enlarged spleen relates to blood cell issues in patients with myeloproliferative disorders and finds that spleen size may indicate disease severity.

Contribution

The study identifies a novel correlation between splenomegaly and cytopenias in myeloproliferative disorders.

Findings

Splenomegaly was present in 68.5% of patients with myeloproliferative disorders.

Massive splenomegaly correlated with greater symptom burden and pancytopenia.

Spleen size may serve as an indicator of disease severity in MPD management.

Abstract

The relationship between splenomegaly and cytopenias in myeloproliferative disorders (MPDs) remains poorly defined despite its clinical
importance. This analytical cohort study evaluated 124 patients with MPDs, including polycythemia vera, essential thrombocythemia, and
primary myelofibrosis, to characterize associations between splenic enlargement and hematologic abnormalities. Splenomegaly was present
in 68.5% of patients and showed significant correlations with anemia and thrombocytopenia. Individuals with massive splenomegaly demonstrated
greater symptom burden and more pronounced pancytopenia. These findings suggest that splenic size may serve as an important indicator of
disease severity and may guide early therapeutic decision-making in MPD management